Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995812 | 0.90 | FLT3 (0.43) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4995804 | 0.90 | FLT3 (0.43) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4998774 | 0.84 | PDGFRB (0.43) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4998771 | 0.84 | PDGFRB (0.43) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4994821 | 0.83 | FLT3 (0.50) | FLT3PDGFRBKDRFGFR1MET | |
| SCHEMBL4994823 | 0.83 | FLT3 (0.50) | FLT3PDGFRBKDRFGFR1MET | |
| SCHEMBL4991096 | 0.83 | PDGFRB (0.44) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4991105 | 0.83 | PDGFRB (0.44) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4997102 | 0.81 | SCN5A (0.45) | FLT3PDGFRBKDRFGFR1KIT | |
| SCHEMBL4997104 | 0.81 | SCN5A (0.45) | FLT3PDGFRBKDRFGFR1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | FLT3 255/4885PDGFRB 307/4885KDR 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.